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Sllmmsr~ 
The cellular infiltrates of certain inflammatory processes found in parasitic infection or in allergic 
diseases consist predominantly of eosinophilic granulocytes, often in association with activated 
T cells. This suggests the existence of chemotactic agonists specific for eosinophils and lymphocyte 
subsets devoid of neutrophil-activating properties. We therefore examined four members of the 
intercrine/chemokine superfamily of cytokines  (monocyte chemotactic peptide  1  [MCP-1], 
RANTES, macrophage inflammatory protein 1ix [MIP-ltx], and MIP-1/3), which do not activate 
neutrophils, for their ability to affect different eosinophil effector functions. R.ANTES strongly 
attracted normal human eosinophils by a chemotactic rather than a chemokinetic mechanism 
with a similar efficacy as the most potent chemotactic myeloid cell agonist, C5a. MIP-ltx also 
induced eosinophil migration, however, with lower efficacy. RANTES and MIP-lo~ induced 
eosinophil cationic protein release in cytochalasin B-treated eosinophils, but did not promote 
leukotriene C4 formation by eosinophils, even after preincubation with interleukin 3 (IL-3), in 
contrast to other chemotactic agonists such as C5a and formyl-methionyl-lencyl-phenylalanine 
(FMLP). RANTES, but not MIP-ltx, induced a biphasic chemiluminescence  response, however, 
of lower magnitude than C5a. RANTES and MIP-lo~ both promoted identical transient changes 
in intracellular free calcium concentration ([Ca2+]i), with kinetics similar to those induced by 
chemotactic peptides known to interact with G protein-coupled receptors. No cross-desensitization 
towards other peptide agonists (e.g., C5a, IL-8, FMLP) was observed,  suggesting the presence 
of specific receptors.  Despite its weaker eosinophil-activating properties, MIP-lol was at least 
10 times more potent on a molar basis than R.ANTES at inducing [Ca  2+ ]i changes. Interestingly, 
RANTES deactivated  the MIP-lcz-induced [Ca2+]i changes, while the R.ANTES response was 
preserved after MIP-lcz  stimulation. MCP-1, a potent monocyte chemoattractant and basophil 
agonist, as well as MIP-1/3, a peptide with pronounced homology to MIP-lo~, did not activate 
the eosinophil functions tested. Our results indicate that R.ANTES and MIP-ltx are crucial mediators 
of inflammatory processes in which eosinophils predominate. 
E 
osinophil granulocytes (eosinophils), similar to other leu- 
kocytes, can leave the circulation and accumulate at inflam- 
matory sites. Chemoattractants produced at the site of inflam- 
mation have been implicated in the induction of leukocyte 
migration into the inflamed tissue and the subsequent acti- 
vation of these effector cells. However, the cellular composi- 
tion of the leukocyte infiltrate (monocytes, lymphocytes, 
basophils, eosinophils, and neutrophils) is distinct in inflam- 
matory reactions of different etiologies, suggesting the exis- 
tence of chemoattractants specific for either one or only a 
few leukocyte types. It is still unclear how such a "specificity" 
of a certain type of an inflammatory response is determined, 
since the chemotactic factors discovered some time ago, such 
as C5a, FMLP, and platelet-activating factor (PAF) 1, attract 
and activate all myeloid cell types. For example, no specific 
eosinophil chemotactic agonist devoid of neutrophil-activating 
properties has yet been identified, with the exception of CD4 
binding proteins recently reported to attract eosinophils (1). 
Nevertheless,  even  in  the  absence  of target  cell-specific 
1Abbreviations used in  this paper: [Ca2+]i, intracellular flee calcium 
concentration; ECP, eosinophil cationic protein; LTC4, leukotriene C4; 
MCP, monocyte chemotactic peptide; MIP, macrophage inflammatory 
protein; NAP, neutrophil-activating  peptide; PAF, platelet-activating  factor; 
RANTES, regulated upon activation in normal T cells expressed and 
secreted. 
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may  also be controlled  by the  presence  of "modulatory" 
cytokines, particularly hematopoietic growth factors. For in- 
stance,  II.-3 and II.-5 enhance the different cellular responses 
of eosinophils and basophils, but not neutrophils,  towards 
diverse chemotactic agonists  (2-6). 
The discovery of a large group of homologous cytokines 
that belong to the platelet factor 4/intercrine/chemokine su- 
perfamily has led to the identification  of chemotactic pep- 
tides with a rather restricted target cell specificity (reviewed 
in references 7-10).  Most members of the C-X-C branch (ac- 
cording to the position of the first two cysteines in the con- 
served  motif),  such  as  IL-8/neutrophil-activating  peptide 
1 (NAP-l),  NAP-2,  gro/macrophage  inflammatory protein 
2 (MIP-2) peptides, and ENA-78, are relatively specific neu- 
trophil attractants (7, 8, 11-14), with the exception of IL-8, 
which may also have some lymphocyte chemotactic activity 
(15) and weakly attracts and/or activates IL-3- or Ib5-primed 
eosinophils and basophils (3, 6, 16). By contrast, the members 
of the human C-C branch of chemokines, such as RANTES, 
MIP-lcz,  MIP-I~,  and  monocyte  chemotactic  peptide  1 
(MCP-1), do not seem to activate neutrophils but rather are 
chemotactic for different mononuclear cell types. MCP-1 is 
a potent monocyte chemoattractant (8-10, 17), while others, 
such as RANTES and MIP-lol, preferentially induce the migra- 
tion  of lymphocyte subsets (10,  18). 
Helminthic  infections and allergic as well as certain  au- 
toimmune diseases are associated with an eosinophilic infiltra- 
tion of the affected tissue. Furthermore, eosinophils and lym- 
phocytes tend to appear in the same type of inflammatory 
lesions in the absence of a marked neutrophilic  infiltration 
(19, 20), suggesting the existence of (a) common agonist(s) 
for  lymphocytes  and  eosinophils  devoid  of  neutrophil- 
activating properties. The recent discovery of potent basophil- 
activating properties of MCP-1 (21, 22) further suggests that 
some family members  of the  C-C branch  of chemokines 
may activate distinct granulocytic effector cell types such as 
eosinophils.  For  these  reasons,  we  investigated  the  effect 
of MCP-1,  MIP-lot,  MIP-1/$,  and  RANTES  on  different 
effector functions of normal human eosinophils purified to 
homogeneity. 
Materials and Methods 
Pept/des.  Natural human C5a was purified to homogeneity from 
yeast-activated  human serum (5). Recombinant human (rhu)MCP-1 
was obtained  from Prepro Tech. Inc. (Rocky Hill,  NJ). 
Recombinant  RANTES, huMIP-lcr  and huMIP-IB were pro- 
duced in Escherichia  coli by linking cDNAs encoding the mature, 
secreted forms of the molecules (devoid of the mammalian signal 
sequence) to the bacterial STII promoter in an expression plasmid. 
Recombinant E. coli expressing human RANTES were harvested 
by centrifugation,  the extracellular medium was discarded, and the 
cell pellet was stored frozen at  -70~  Cell pastes were thawed 
and dispersed in 50 mM glycine, 250 mM NaC1, pH 3.0, using 
an Ultra Turrax homgenizer (Tekmar Corp., Cincinnati, OH). The 
cells were then mechanically disrupted in a homogenizer  (1104; 
Microfluidics, Newton, MA) operating at 23,000 psi cooled to room 
temperature.  Cell debris were removed by centrifugation,  the su- 
pernatant adjusted to pH 6.0, and loaded onto an S-Sepharose fast 
flow column (Pharmacia, Uppsala, Sweden) equilibrated in 20 mM 
sodium citrate, pH 6.0. The bound material was duted with a linear 
gradient of 0-1.0 M NaC1. Reverse-phase (RP)-HPLC analysis of 
eluted  fractions  (using an 8-/~m, 4,000-11  resin [Polymer Labs, 
Amherst,  MA] and a linear gradient from 10 to 60% acetonitrile 
in 0.1% TFA, at 50~  showed that the peak RANTES levels oc- 
curred at ,o0.7 M NaC1. The S-Sepharose pool was conditioned 
by addition of solid ammonium sulfate to 1.8 M, and loaded onto 
a Phenyl Toyopearl column  (Tosa-Haas, Inc.,  Philadelphia,  PA) 
equilibrated in 100 mM sodium phosphate, pH 6.0. Bound protein 
was eluted with a linear gradient  (1.5-1.0 M) ammonium sulfate 
in 100 mM sodium phosphate, pH 6.0. RANTES-containing  frac- 
tions were selected for pooling by ILP-HPLC, and ammonium sul- 
fate was removed by diafiltration versus 10 mM sodium citrate, 450 
mM NaC1, pH 5.0, across a 3-kD cutoff membrane,  huMIP-lcz 
was purified from E. coli fermentation medium after first removing 
the cells by low-speed centrifugation.  The pH of the supematant 
was then adjusted to ,v3 with phosphoric acid, and the resulting 
precipitate was removed by a second low-speed spin. After adjust- 
ment to pH 5, the huMIP-lc~ contained in the clear supernatant 
was captured on a bare silica column and eluted with 15% eth- 
anol/1  M NaC1. The silica pool was diafiltered into 10 mM Tris 
buffer at pH 7 and loaded onto a DEAE-Sepharose column, from 
which huMIP-lc~ was duted with 0.3 M NaC1 in Tris buffer. The 
product was further purified by C4 RP-HPLC (Waters radial com- 
pression cartridge) using a linear gradient of acetonitrile. Solvent 
was removed by capture and elution from DEAE-Sepharose as de- 
scribed above, and the purified product was formulated for adminis- 
tration by diafiltration into an isotonic dtrateAodium chloride buffer. 
huMIP-lB was purified from recombinant E. coli by dispersing 
cell paste in phosphate buffer at neutral pH, followed by homogeni- 
zation at ,o20,000 psi. The homogenate was adjusted to pH 3 and 
centrifuged briefly to pellet cell debris. The supematant was decanted 
and adjusted to pH 6 with sodium hydroxide, initiating the precipi- 
tation of huMIP-1B. After centrifugation,  the supernatant was dis- 
carded and the pellet dissolved with ,ol M NaC1/20 mM acetic 
acid, pH 3. This solution was then applied to a column of phenyl 
Toyopearl equilibrated in the same buffer. After analysis by RP- 
HPLC, selected fractions of the column flow-through were pooled 
and diafiltered across a 5-kD cellulose membrane versus 20 mM 
acetic acid, pH 3.2. 
Purity as judged by HPLC was >99% for all peptides and the 
pyrogen content was <1 endotoxin unit (EU)/mg for RANTES 
and MIP-lot and <5 EU/mg for MIP-1/~ as determined by limulus 
amoebocyte lysate test. All peptides were stored in Hepes buffer 
containing  1 mg/ml BSA in small aliquots at  -70~  and added 
to the cells at  1:1,000 to 1:100 (vol/vol) ratio. 
Purification  of  Eosinophils.  Eosinophils  were  purified  from 
dextran-sedimented  leukocytes (6% dextran  T70 [Pharmacia] in 
0.9% NaC1) of EDTA anticoagulated blood (10 mM EDTA; Fluka 
AG, Buchs, Switzerland) of normal human volunteers exactly as 
described (23) using a combination of discontinuous Percoll gradient 
centrifugation  and negative selection with anti-CD16-coated im- 
munomagnetic  microbeads (Miltenyi Biotec, Bergisch-Gladbach, 
Germany), except that the Percoll density used was higher (1.090g/ 
ml) in order to further enrich the eosinophils and to save  anti-CD16 
beads. The resulting eosinophil purity was >99.5% as determined 
by microscopic examination of Giemsa-stained cytospin prepara- 
tions. All rare contaminating  cells were neutrophils.  After isola- 
tion,  cells were resuspended in HACM buffer  (20 mM Hepes; 
Calbiochem-Behring  Corp., La Jolla, CA; 125 mM NaC1, 5 mM 
KC1, 0.5 mM glucose, 0.025% BSA, fatty acid free, low endo- 
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CaC12 and I mM MgCI2) in all experiments at the concentrations 
indicated, except in chemotaxis assays, for which a HBSS containing 
Ca  2+  and Mg  2+  supplemented with 0.05% BSA was used. 
Respiratory Burst of Normal Human Eosinophils.  Oxygen radical 
production of eosinophils was assessed by measuring the H202/ 
peroxidase--dependent  chemiluminescence of luminol exactly as de- 
scribed  (24)  using 5  x  10  ~ pure eosinophils  in 500/~1  HACM 
buffer containing 10 U/ml horseradish peroxidase and 10/~M tu- 
minol (both from Sigma Chemical Co., St. Louis, MO), with the 
exception that NaN3 (for inhibition of cell-derived  myeloperoxi- 
dase)  was  omitted since no granule release  occurred under  the 
experimental conditions.  Chemiluminescence was  continuously 
monitored in a six-channel chemiluminometer (Biolumat LB505; 
Berthold Laboratory, Berlin, Germany) at time intervals  of 10 s. 
Eosinophil Cationic Protein (ECP) Release and Leukotriene C~ 
(LTC~) Generation.  Cytochalasirr B  (5  min  at  5 /~g/ml after a 
warm-up period of 10 min at 37~  Sigma Chemical Co.)-treated 
eosinophils (3  x  10  s cells/ml) in HACM buffer were exposed to 
the peptides for 20 min. Then, the cells were placed on ice, and 
ECP was released into the supernatants obtained after centrifuga- 
tion (10 rain at 4~  and 500g) was measured by RIA (Pharmacia). 
Total ECP content was determined from cell lysates obtained after 
three freeze/thaw cycles. Leukotriene generation by eosinophils 
pretreated with and without Ib3 (30 ng/ml) was determined as 
described previously (4,  25). 
Changes of lntracelhlar Calcium Concentration ([Ca2+~).  Purified 
eosinophils were loaded with 0.3  nmol fura-2/AM  (Fluka AG, 
Buchs, Switzerland) per 106 cells in HACM buffer for 30 rain at 
37~  After a short centrifugation (5 rain, 150 g, room tempera- 
ture) the freshly loaded cells were resuspended in prewarmed HACM 
buffer at a concentration of 0.5-2  x  106 cells/ml. Fura-2 fluores- 
cence changes (excitation wavelength, 340 nm; emission wavelength, 
>490 nm) of the cell suspensions in response to cell agonists were 
continuously monitored at 0.25-s intervals and analyzed as described 
(14, 22). Each measurement was standardized by adding ionomycin 
(5 #M final concentration; Sigma Chemical Co.) leading to 100% 
fura-2 saturation and subsequent quenching of the fluorescence with 
MnC12 (1 mM final concentration). 
Measurement of In  Vitro Eosinophil Chemotaxis.  Eosinophil 
chemotaxis assays were performed as described (26).  Briefly, eo- 
sinophils  (l@/ml)  were  placed  in  the  top  wells  of a  48-well 
chemotactic chamber (Neuroprobe, Cabin John, MD), which were 
separated  from the bottom wells containing buffer or peptides at 
the concentrations indicated by a polycarbonate filter with 5-/~m 
pores (Nudeopore, Pleasanton, CA). For testing chemokinetic re- 
sponses of eosinophils to RANTES, the cytokine was added to the 
bottom, the top, or on both sides of the filter. The chambers were 
disassembled  after a 1-h incubation at 37~  in 5% CO2, a time 
point previously established to be optimal for eosinophil migration 
(26). The eosinophils  that migrated across the filter and adhered 
to the bottom side of the filter were stained with Giemsa (Merck, 
Darmstadt, Germany) and counted in a randomly chosen area of 
1 mm  2 corresponding to each well by an Optomax V image ana- 
lyzer (AiTektron, Meerbusch, Germany). The number of eosinophils 
obtained was multiplied by eight to get the total number of migrated 
eosinophils for each well (well diameter, 3.2 mm). The number 
of migrated nonadherent (drop-off) eosinophils was determined in 
two experiments. For each concentration, the number of drop-off 
cells was found to be proportionate to the number of eosinophils 
adherent to the filter and to constitute <20% of the total migrated 
cell number. Since the adherent eosinophils  were representative of 
the total migrated eosinophil population, all of the results from 
the chemotaxis experiments were expressed as the mean number 
of migrated adherent eosinophils  (in percent of the total input). 
For each tested attractant, the mean chemotactic ef~cacy (number 
of eosinophils migrated at the optimal chemotactic concentration) 
and mean migration index (number of cells that migrated at the 
optimal chemotactic concentration divided by the number of cells 
that migrated to buffer control) were determined. All experiments 
were performed in duplicates  or triplicates  and repeated at least 
five  times  with  eosinophil preparations  from different donors. 
Statistical  analysis was  performed using the student's t test. 
Results 
Chemotactic  Activity  of RANTES  and  Related  Peptides. 
Among the/3-intercrines/chemokines tested, RANTES and, 
to a much lesser extent, MIP-lc~ induced the migration of 
eosinophils above the level of random migration in a concen- 
tration-dependent manner (Fig. 1). In five experiments with 
different  eosinophil  preparations,  RANTES  had  a  mean 
chemotactic efficacy of 40.9  _+ 6% (SEM) and a mean migra- 
tion index of 5.7  +_  0.7  (SEM) at  10 -7 M,  whereas MIP- 
ltx, at its optimal 10-S-M concentration, attracted fewer eo- 
sinophils (mean efficacy, 15.5  +  1.9%; mean migration index, 
2.4  _+  0.3; p  <  0.05 versus buffer control).  C5a,  a potent 
chemotactic agonist for all mydoid cells, including eosinophils, 
was used as a positive control and attracted at its optimal 
10-S-M  concentration  43.7  _+  6.7%  (SEM)  eosinophils 
(mean migration index,  6.1  _+  0.5).  Eosinophil migration 
in response to MCP-1 and MIP-I~ did not significantly differ 
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Figure  1.  Migration  of  pure  human  eosinophils  in  response  to 
chemokines. Buffer controls (0) or the peptides at the concentrations in- 
c~cated (abscissa)  wel"e  placed  in the bottom wells  of the chemotaxis  chamber. 
C5a (10 riM) was included  for comparison. Migration (ordinate)  is expressed 
as the percentage  of the total number of cells added to the chamber. Mean 
values _+ SD of one experiment performed in triplicates out of five are 
shown. 
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Figure 2.  Chernotaxis  vs. chemokinesis  of cosinophils  in response to 
RANTES. RANTES was placed in the bottom (circles), in the top (tr/- 
aagles),  or on both sides (squares) of the falters at the concentrations  indi- 
cated.  Otherwise, experimental  conditions  and presentation  of the data 
are as in Fig.  1. 
from that of the buffer control (mean migration indexes of 
1.4  _+ 0.2 and 1.2  _+ 0.2, respectively). Fig. 2 demonstrates 
that the eosinophil migration induced by R.ANTES was due 
to a chemotactic rather than a chemokinetic  mechanism since 
the response was negligible when the peptide was placed ei- 
ther in the top well only or on both sides of the filter. 
Oxygen Radical-induced  Chemiluminescence  Response of  Hu- 
man Eosinophils.  RANTES, in contrast to MIP-lo~, MIP- 
1~/, and MCP-1, induced a biphasic chemiluminescence re- 
sponse in human eosinophils at 10 -7 M (Fig. 3 A). The Ib8 
response was negligible, in agreement with previous studies 
using eosinophils form hypereosinophilic donors (27). How- 
ever, when compared with the response to C5a, which is the 
most potent chemotactic agonist for the induction of the re- 
spiratory burst by eosinophils (27), R.ANTES induced the 
production of dearly smaller amounts of oxygen radicals 
(Fig. 3 B). 
Eosinophil Degranulation and LTC4 Generation.  A number 
of previous studies have shown that the chemotactic factor 
agonists examined so far promote granule release by neutro- 
phils and eosinophils (12, 14, 27), provided that the cells have 
been pretreated with cytochalasin B. Consistent  with their 
chemotactic activity on eosinophils,  RANTES as well  as 
MIP-lo~ induced the release of ECP at  10-s-10 - 7 M con- 
centrations, in contrast to MIP-lfl, MCP-1, and I1-8, which 
were ineffective (Fig. 4). At 10-7 M, RANTES promoted 
a more pronounced degranulation response than MIP-lc~. 
However, maximal effects induced by MIP-lc~ were reached 
at lower (>--10  -s M) concentrations.  When compared with 
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Figure 3.  Oxygen radical-in- 
duced chemiluminescence in pure 
normal eosinophils in response to 
peptide agonists. 0.5  x  103 cells 
in 500-/~1 aliquots  were warmed 
up  for  10  rain  at  37~  before 
adding  the peptides  indicated  at 
10-~ M. Oxygen radical produc- 
tion was assessed by the H202/ 
peroxidase-induced  chemilumi- 
nescence of luminol as described 
in Materials and Methods.  Rep- 
resentative recordings of chemilu- 
minescence  (in cpm)  over  time 
(10-s intervals) are shown. Arrows 
indicate the time ofpeptide addi- 
tion. Identical kinetics were ob- 
tained in six different experiments. 
Chemihminescence  of resting eo- 
sinophils  was  234  _+  61  x  103 
cpm. Peak chemiluminescence in- 
duced by R.ANTES was 5,083  -+ 
863  x  103 cpm and C5a 88,450 
•  2,192  x  103 cpm (mean  +_ 
SD) in six experanents.  (A) Chemiluminescence  induced by chemokines. 
The recordings  after MCP-I addition  were identical  to that of MIP-1B 
(not shown).  (B) Comparison to the response induced by C5a (100 nM). 
Note the difference in scale between A  and B. 
C5a and FMLP (27), RANTES and MIP-lc~ induced the re- 
lease of considerably less ECP (Fig. 4). 
Our previous studies showed that the chemotactic agonists 
FMLP and CSa induce the generation of LTC4 by IL-3- 
pretreated  eosinophils.  FMLP, but not C5a,  also leads to 
LTC4  synthesis  by  freshly  isolated  normal  human  eo- 
sinophils, albeit in smaller amounts than by I1"3-primed eo- 
sinophils (4). By contrast, neither RANTES nor MllXlol were 
capable of promoting the generation of detectable amounts 
of LTC4 even by eosinophils preincubated for 90 min with 
30 ng/ml II.-3 (<30 pg LTC4/IO  6 eosinophils formed in re- 
sponse to R.ANTES or MIP-lc~ at 10-7 M with or without 
preincubation  with 30 ng/ml II-3 during 90 rain in experi- 
ments performed with cells from five  different donors in which 
C5a and FMLP were included  as positive controls). 
Changes of[Ca2+]i.  Chemotactic myeloid cell agonists 
are known to rapidly induce a transient change in [Ca2+]i 
as an early event of receptor-mediated signal transduction (7, 
11,  12,  14, 22, 27). Similarly to other chemotactic peptide 
control 
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M~P~1a 1C-'TM 
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MCP-1 10-7M 
IL-8 10-7M 
CSa 10-7M 
fMLP 10-6M 
0 
1 
200  400  600  800  1000 
ECP (ng/106  eosinophils) 
Figure 4.  ECP release by hu- 
man eosinophils. Pure eosinophils 
(300,000  cells/ml)  were  treated 
with cytochahsin B (5 ~g/ml) for 
5 min before adding the peptides 
at the concentrations indicated for 
20 rain. ECP released into the su- 
pernatant  (mean  _+  SD of three 
experiments)  is shown.  ECP re- 
lease induced by C5a corresponds 
to 65% of the total cellular ECP 
content. 
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Figure 5.  Changes of [Ca2+]i 
in eosinophils  induced by peptide 
agonists. Fura-2-1oaded  ceils  were 
suspended at  2  x  106/ml and 
continuously monitored for fluo- 
rescence  changes. Peptide  agonists 
were added at the time points in- 
dicated by arrows in 1:200 dilu- 
tions (vol/vol), resulting in final 
concentrations of 50 riM. [Ca2+]i 
changes in response  to the sequen- 
tial addition of MClXl, MIP-I~, 
RANTEg IL-8, and CSa (A), and 
of MIP-1/~, RANTES, MIP-I~, 
IL-8, and C5a (B). Identical results 
were obtained with cells of five 
different blood donors, with the 
exception that the response  to IL-8 
was in some experiments even smaller than shown here. The order of ad- 
dition of C5a, IL-8, and KANTES or MIP-ta did not alter the [Ca2+]i 
changes induced by each agonist (not shown). 
agonists such as C5a, R.ANTES and MIP-lot induced rapid 
and transient [Ca2+]i changes.  MCP-1 and MIP-lfl, however, 
were ineffective (Fig. 5). Despite their marked difference in 
chemotactic efficacy and despite the inability of MIP-lo~ to 
induce a respiratory burst, as opposed to RANTES, the ex- 
tent  and kinetics of the [Ca  2+]i changes were virtually in- 
distinguishable  at  100 and 50 nM for both peptides (Figs. 
5 and 6). Dose-response studies even revealed that MIP-lct 
was at least 10 times more effective on a molar basis as com- 
pared with  R.ANTES  (EDs0 for maximal  [Ca2+]i  increase 
"~  lOOnM  "~ 50nM 
10nM  ~50nM  ~  10nM  ~ 5OhM 
lnM  ~50nM  ~  3riM  ~ 50nM 
o  2~ 
1'  0 n.  I' 0.M  ,  ,  I'  ,~ 
MIP-lcz  RANTES  1 min  RANTES  MIP-lo~ 
Figure 6.  Cross-densensitization of  [Ca2+]i changes induced by 
RANTES and MIP-I~ in eosinophils. Experimental conditions are as in 
Fig. 5. (A) Eosinophils were exposed to decreasing concentrations (100, 
10, 1, 0.3 riM, respectively)  of MIP-lot followed  by a constant quantity 
of RANTES (50 nM final concentration) 90 s later. (B) RANTES (100, 
10, 3, 1 riM, respectively)  was followed  by MIP-I~ addition (50 nM). 
for RANTES at 3-10 nM, EDso for MIP-lo~ at 0.3-1 nM) 
for inducing  transient  [Ca2+]i  changes (Fig.  6). 
No  information  is yet  available  on  the  expression  and 
specificity of receptors for MIP-lo~ and RANTES on human 
leukocytes. When cells have been exposed to a certain cell 
agonist capable of inducing [Ca  2+ ]i responses at sufficiently 
high concentrations,  a second [Ca2+]i change is abolished if 
the same peptide or a different agonist interacting with a shared 
receptor is used as a second trigger (11, 12, 14, 22, 28). This 
phenomenon has been referred to as receptor-specific cell desen- 
sitization. By contrast, we found negligible mutual influence 
of  sequential  [Ca2+]i  responses  for  a  variety  of  diverse 
agonists interacting with separate receptors in different effector 
cell types. (22, our unpublished observations). Therefore, to 
examine whether RANTES and MIP-lc~ activate eosinophils 
through specific receptors,  [Ca  2+ ]i changes were monitored 
in eosinophils sequentially exposed to different agonists in 
various combinations.  Exposure of eosinophils  to MIP-lol 
and/or  RANTES  affected neither  the  [Ca2+]i  response to 
Ilo-8 nor CSa (Fig.  5) and vice versa (data not shown). Fig. 5 
also demonstrates the poor effectiveness of I1.-8 for inducing 
[Ca  2+ ]i changes,  consistent with its predominant neutrophil- 
activating properties  and previous studies performed with 
hypereosinophilic cells (3, 27). Furthermore, exposure ofeo- 
sinophils to RANTES or MIP-lc~ did not affect the [Ca2+]i 
changes induced by two other unrelated chemotactic agonists, 
FMLP and PAF (data not shown). Sequential addition of the 
two members of the C-C subfamily of chemokines, RANTES 
and MIP-lo~,  however, resulted in alterations of the second 
signal (Figs.  5 and 6). Most surprising was the observation 
that  RANTES at 50 and 100 nM almost totally abolished 
the  [Ca2+]i  changes  induced by MIP-lo~ despite its  lower 
potency in promoting [Ca2+]i changes by itself (as compared 
with MIP-lc  0, while preincubation with MIP-la even at 100 
rim hardly affected the eosinophil response to RANTES (Figs. 
5 and 6).  Fig.  6 also shows the concentration  dependency 
of these deactivation phenomena. 
Discussion 
The members of the intercrine/chemokine family of pep- 
tides are small molecular mass cationic cytokines (7-10 kD) 
whose major biological function lies in their chemotactic ac- 
tivity towards different leukocyte effector cells (7-10).  For 
the members of the C-X-C or Ib8 subfamily, much progress 
has been made regarding their biological functions and char- 
acterization of specific receptors, in contrast to the members 
of the C-C subfamily for which information is still scarce (10). 
So far,  the best examined cytokine of the C-C family is 
MCP-1, a potent attractant  and activator of human mono- 
cytes (8-10,  17).  R.ANTES has recently been shown to be 
a chemotactic factor of lymphocytes of Th memory subsets 
(18).  This  study demonstrates  that  RANTES,  and  more 
weakly MIP-lo~,  in contrast to MCP-1 and MIP-1/~, are also 
chemotactic for eosinophils. RANTES was found to be a par- 
ticularly efficacious chemoattractant for eosinophils,  attracting 
almost as many eosinophils at optimal concentrations as the 
most potent known chemotaxin,  C5a. In comparison with 
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ygen radical production, ECP release) or an ineffective (LTC4 
synthesis) activator of human eosinophil effector function. 
None of the C-C members examined (R.ANTES, MIP-lc~, 
MCP-1, MIP-1B) were, however, capable of activating neu- 
trophils, at least at concentrations up to 100 nM (10, 22, our 
unpublished observations). Thus, RANTES and MIP-lol ap- 
pear to be the first recognized peptide agonists chemotactic 
for eosinophils but not for neutrophils. 
Calcium measurements indicated that RANTES and MIP- 
lc~ activate human eosinophils through specific receptors. The 
kinetics of [Ca2+]i changes in response to  RANTES  and 
MIP-loL in eosinophils are similar to those induced by other 
humoral and cell-derived chemotactic agonists, such as C5a 
and IL-8 in neutrophils, suggesting that these cytokines in- 
teract with G  protein-coupled receptors.  Although cross- 
desensitization experiments are only a preliminary and in- 
direct way of demonstrating the specificity of novel receptors, 
previous studies in other myeloid cell types with all agonists 
performed so far (C5a, C3a, FMLP, PAF, IL-8, NAP-2) have 
revealed an excellent predictive value of this experimental ap- 
proach (11, 12, 28).  In fact, in all myeloid cells,  sequential 
challenge with 100 nM of any of these agonists results in 
complete desensitization towards a second challenge with the 
same agonist (our unpublished observations). Thus, the ina- 
bility of MIP-lo~ and RANTES to affect [Ca2+]i change to- 
wards other peptide agonists indicates that eosinophils ex- 
press  novel yet  to  be  defined receptors  specific  for  these 
cytokines. The mutual influence of RANTES and MIP-lot 
on each other's [Ca2+]i response is more difficult to interpret. 
The data shown in Fig. 6 would be consistent with the exis- 
tence of two types of receptors recognizing RANTES and 
MIP-lc~,  respectively, one being specific for RANTES and 
the other recognizing MIP-I~ with high and tLANTES with 
lower affinity. This interpretation is also consistent with the 
presented data on eosinophil function: R.ANTES, as opposed 
to MIP-lo~, has the capacity to activate the respiratory burst 
of eosinophils and has a higher efficacy in promoting eosino- 
phil chemotaxis and degranulation at maximally effective con- 
centrations. MIP-lo~, however, on a molar basis is consider- 
ably  more  potent  than  RANTES  in  inducing  [Ca2+]i 
changes and ECP release. The capacity of MIP-lc~ to induce 
[Ca2+]i changes at low concentrations together with its rel- 
atively poor eosinophil activating properties may indicate that 
MIP-lo~ could be a specific agonist for another, yet to be de- 
termined, cellular response in eosinophils, such as gene ex- 
pression or cell survival. 
MCP-1 was unable to activate eosinophils in all the cell 
functions tested and did not induce [Ca2+]i changes, sug- 
gesting that eosinophils do not express MCP-1 receptors and 
that  MCP-1  cannot  interact  with  MIP-lo~  or  RANTES 
receptors, respectively,  on eosinophils. Apart from being a 
monocyte chemoattractant, MCP-1 has recently been shown 
to represent the most potent cell-derived basophil agonist (21, 
22). Our studies performed so far revealed that basophils and 
eosinophils are closely related effector cell types with regard 
to the profile of cytokines and cell agonists regulating the 
function of these myeloid cell types (4-6). Thus, MCP-1 ap- 
pears to be the first basophil trigger incapable of activating 
eosinophils.  On the other hand, in addition to the effects 
on eosinophils as reported here, R.ANTES was also found 
to  be  a  potent  chemotactic factor  for basophils  without 
strongly activating other basophil effector function (our un- 
published observations). It therefore appears  that the main 
function of RANTES lies in its ability to attract particular 
sets of leukocytes, namely Th cell subsets,  eosinophils, and 
basophils, without affecting neutrophil functions. Despite the 
fact that MIP-I~ is more homologous to MIP-lcr than MIP- 
lcr  to RANTES (10), MIP-1B did not activate eosinophils 
nor induce [Ca  2+ ]i changes, and did not desensitize the MIP- 
lol or RANTES response. This observation is particularly 
surprising if one postulates the existence of one receptor type 
recognizing both MIP-lol and RANTES. 
The effects of R.ANTES and MIP-lot on eosinophil func- 
tion may explain, at least in part, why eosinophilic cellular 
infiltrates largely devoid of neutrophils can be observed in 
different diseases. Furthermore, eosinophilic inflammation is 
often associated  by concomitant infiltration with activated 
T  helper cells, an association that can be explained by the 
chemotactic effect of RANTES and/or MIP-loe on these two 
cell types (29, 30).  RANTES and MIP-lcr may thus be par- 
ticularly important mediators of immediate-type hypersensi- 
tivity diseases, such as asthma, by promoting the selective 
attraction and/or activation of eosinophils, basophils,  and Th 
cells that are found to dominate in allergic inflammatory sites. 
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